Despite these setbacks, MDM2 inhibitors such as navtemadlin and brigimadlin continue to advance in clinical development, with multiple ongoing Phase II and III trials investigating their efficacy in malignancies, including myelofibrosis and glioblastoma. This evidence concerns the gene MDM2 and glioblastoma.